
Sign up to save your podcasts
Or


James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.
By John Simboli5
77 ratings
James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

534 Listeners

3,072 Listeners

1,091 Listeners

940 Listeners

795 Listeners

125 Listeners

322 Listeners

96 Listeners

9,942 Listeners

34 Listeners

519 Listeners

146 Listeners

349 Listeners

182 Listeners

467 Listeners